Merck Serono, Galderma breach ABPI code; Health Canada hands-off when regulating DTC drug ads, study finds;

> The Prescription Medicines Code of Practice Authority has found Merck KGaA's Serono unit and Galderma guilty of the most serious breach of the ABPI Code of Practice. Report

> Health Canada is indifferent to enforcing its own regulations when it comes to prescription drug ads targeted to health consumers, a new study has found. Report

> If the total number of new HCV patients doubles in 2014, there will be room for the forthcoming crop of hep C competitors, a Morgan Stanley analyst says. More

> Sun Pharma may retire the Ranbaxy brand while retaining sub-brands like Volini and Revital. Report

> Novartis' ($NVS) Sandoz biosimilar copy of Amgen's ($AMGN) Neupogen showed similar efficacy in a late-stage study. Report

> Barnum Communications founder Dr. James Barnum and Lewis and Gace cofounder Francis Gace have been selected as 2015 inductees into the Medical Advertising Hall of Fame. Story

And Finally... BlackBerry is targeting doctors and nurses who use its smartphones with its first healthcare app. More

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.